CytomX Therapeutics, Inc.·4

Jan 29, 6:57 PM ET

RAY DEBANJAN 4

4 · CytomX Therapeutics, Inc. · Filed Jan 29, 2019

Insider Transaction Report

Form 4
Period: 2019-01-25
RAY DEBANJAN
Chief Financial Officer
Transactions
  • Award

    Stock Option (right to buy)

    2019-01-25+90,00090,000 total
    Exercise: $16.85Exp: 2029-01-24Common Stock (90,000 underlying)
Footnotes (1)
  • [F1]1/48th of the shares subject to the option vest on each monthly anniversary measured from January 1, 2019 (the "Vesting Commencement Date"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, subject to the Reporting Person's continued service to the Issuer through each such date.

Documents

1 file
  • 4
    doc1.xmlPrimary

    FORM 4